What is IGF-1 and the growth-hormone axis?

The growth-hormone axis at a glance

Insulin-like growth factor-1 (IGF-1) is a signaling protein the body makes, and it is most often discussed as part of a larger endocrine pathway sometimes called the growth-hormone axis, or the GH/IGF-1 axis. Understanding IGF-1 means following a chain of signals that begins in the brain and ends in the liver and other tissues. The axis is usually described as having three tiers, each passing a signal to the next:

• Hypothalamus — a region at the base of the brain that releases growth hormone-releasing hormone (GHRH), the signal that starts the cascade.
• Pituitary gland — responds to GHRH by releasing growth hormone (GH) into the bloodstream.
• Liver and other tissues — respond to circulating GH by producing IGF-1, a downstream messenger.

In this arrangement, IGF-1 is described as a second signal that carries out many of growth hormone's biological actions in tissues around the body. This article is educational only. It describes how the axis is understood to work at a mechanistic level; it is not medical advice, a recommendation, or a statement about what any person should expect. Whether any medication that acts on this pathway is appropriate for a given person is a clinical judgment that belongs to an independent licensed provider.

The hypothalamus and pituitary: GHRH and somatostatin

The top of the axis is a push-and-pull between two hypothalamic hormones. Growth hormone-releasing hormone (GHRH) is the stimulatory signal: it travels the short distance to the pituitary and prompts specialized cells there, called somatotrophs, to synthesize and release growth hormone. Somatostatin is the opposing, inhibitory signal, understood to dampen that release. The balance between these two hormones is what shapes how much growth hormone the pituitary puts out and when.

A defining feature of this system is that growth hormone is not released at a steady level but in bursts, or pulses, across the day and especially during sleep. GHRH is generally described as initiating those pulses, while somatostatin modulates their size and timing. The result is a rhythmic, pulsatile pattern rather than a constant background level — a detail that matters for understanding the downstream signal it produces.

How the liver turns GH into IGF-1

Once released, growth hormone circulates through the bloodstream and binds to growth-hormone receptors on target tissues. The liver is the single largest source of the IGF-1 found in circulation. When GH engages its receptor on liver cells, it is understood to switch on the genes that produce IGF-1, which is then secreted into the blood. Other tissues also make IGF-1 locally, but the liver's contribution is what most blood measurements reflect.

Unlike growth hormone, which rises and falls in sharp pulses, circulating IGF-1 tends to stay relatively stable across the day. Part of the reason is that most IGF-1 does not travel alone: it is carried by binding proteins — chiefly one called IGF-binding protein-3 (IGFBP-3), together with a partner molecule known as the acid-labile subunit. These carriers are understood to extend how long IGF-1 persists in the bloodstream and to regulate how much of it is free to act. Because of this, IGF-1 is often described as a smoothed-out reflection of growth-hormone activity over time rather than a snapshot of any single pulse.

The feedback loops that keep the axis balanced

Like most endocrine systems, the GH/IGF-1 axis is self-correcting through negative feedback. As growth hormone and IGF-1 rise in the bloodstream, they signal back to the hypothalamus and pituitary to quiet further release. IGF-1 is understood to act at both levels: at the hypothalamus it tends to increase somatostatin tone, and at the pituitary it tends to restrain the somatotrophs' response to GHRH. Growth hormone itself also feeds back on the hypothalamus in what is sometimes called a short loop.

The overall effect is often described as a thermostat rather than a simple faucet. When IGF-1 signaling is ample, the brakes come on and the pituitary eases off; when it falls, the restraint lifts and release can rise again. This looping structure is why the axis is described as regulated at several points at once, and it is central to understanding why a molecule acting at any single step does not operate in isolation — the rest of the loop continues to respond around it.

Where a GHRH analog like sermorelin fits

Because GHRH sits at the very top of this axis, it is a point of interest in discussions of the pathway. Sermorelin is one example of a compounded peptide described as a GHRH analog — a molecule built to correspond to the active fragment of the body's own GHRH. In mechanistic terms, it is discussed as acting on the GHRH receptor on pituitary somatotrophs, the same receptor the natural hormone engages. Referencing it here is simply to place a familiar molecule on the map of the axis; it is a neutral example, not a recommendation.

A frequently noted feature of acting at this upstream step is that anything released downstream remains subject to the body's existing controls — somatostatin's opposing tone and the negative feedback from GH and IGF-1 described above. Sermorelin is a peptide, and like most peptides it is not well absorbed when swallowed, so compounded preparations are made for subcutaneous injection rather than as a tablet. Compounded medications are prepared by a licensed pharmacy for an individual patient pursuant to a prescription and are not FDA-approved drugs; statements about them have not been evaluated by the FDA. This is a description of mechanism and form only — whether such a molecule is appropriate for a particular person is a decision for an independent licensed provider, not something this article can determine.

How it works on OpenDoseRx

On OpenDoseRx, a licensed clinician — not the shopper — makes the medical decision. You choose a product and strength, then complete a medical intake with your health history.

An independent, licensed U.S. provider reviews that intake and decides whether a prescription is appropriate for you. If it is, a licensed U.S. pharmacy prepares and ships it; if the provider declines, you are not charged for the medication and receive a full refund. This article is educational only and is not a substitute for a conversation with your own healthcare provider.